Literature DB >> 32420958

Sofosbuvir as a potential option for the treatment of COVID-19.

Anahid Nourian1, Hossein Khalili2.   

Abstract

Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32420958     DOI: 10.23750/abm.v91i2.9609

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


  2 in total

1.  Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial.

Authors:  Sherif Abbass; Ehab Kamal; Mohsen Salama; Tary Salman; Alyaa Sabry; Wael Abdel-Razek; Sherine Helmy; Ahmed Abdelgwad; Neamt Sakr; Mohamed Elgazzar; Mohamed Einar; Mahmoud Farouk; Mounir Saif; Ismail Shehab; Eman El-Hosieny; Mai Mansour; Doaa Mahdi; El-Sayed Tharwa; Mostafa Salah; Ola Elrouby; Imam Waked
Journal:  J Med Virol       Date:  2021-08-24       Impact factor: 20.693

Review 2.  Metal-Based Compounds in Antiviral Therapy.

Authors:  Chiara Abate; Federica Carnamucio; Ottavia Giuffrè; Claudia Foti
Journal:  Biomolecules       Date:  2022-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.